News for Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (ABUS) to present five abstracts at EASL Congress 2025 in Amsterdam. Key findings include the efficacy of Imdusiran and AB-101 in trea

**media[602521]**

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Arbutus Biopharma (NASDAQ:ABUS) stock gains as the company announces a restructuring drive with a 57% workforce reduction. Read more here.

Arbutus (ABUS) delivered earnings and revenue surprises of 12.50% and 17.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with

**media[555746]**

**media[555742]**

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS) (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

Transaction Overview On February 20, 2025, Whitefort Capital Management, LP (Trades, Portfolio) executed a strategic stock transaction involving Arbutus Biophar

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp.

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.

**media[513454]**

Arbutus Biopharma announces 2025 objectives & financial update. Cash balance, reduced net cash burn, Phase 2b clinical trial initiation.

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.